ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN 印刷: 0893-9675
ISSN オンライン: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2019031519
pages 139-148

Nanoparticles in Pancreatic Cancer Imaging and Therapy

Saikrishna Lakkakula
Department of Zoology, Visvodaya Government Degree College, Venkatagiri, India
Gayathri Chalikonda
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322
Bhaskar LVKS
Guru Ghasidas University


Pancreatic cancer (PC) is the fourth leading cause of cancer deaths in both men and women. Because most PC patients are initially diagnosed at an advanced stage of disease, effective diagnostic tests for earlier diagnosis of PC are needed. Several studies have investigated the utility of nanoparticle for both diagnosis and therapy of PC. This review discusses the various engineered nanoparticles currently in use for imaging and therapy. Although nanoparticles have shown considerable clinical promise, complete translation of nanoparticle-based molecular imaging and oncotherapeutic agents has been the challenge.


  1. Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol. 2017;28(5):1117-23.

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.

  3. Thomas G, Chardes T, Gaborit N, Mollevi C, Leconet W, Robert B, Radosevic-Robin N, Penault-Llorca F, Gongora C, Colombo PE, Lazrek Y, Bras-Goncalves R, Savina A, Azria D, Bazin H, Pelegrin A, Larbouret C. HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget. 2014;5(16):7138-48.

  4. de Wilde RF, Hruban RH, Maitra A, Offerhaus GJA. Reporting precursors to invasive pancreatic cancer: pancreatic intraepithelial neoplasia, intraductal neoplasms and mucinous cystic neoplasm. Diagnostic Histopathol. 2012;18(1):17-30.

  5. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-25.

  6. Baldwin S, Kukar M, Gabriel E, Attwood K, Wilkinson N, Hochwald SN, Kuvshinoff B. Pancreatic cancer metastatic to a limited number of lymph nodes has no impact on outcome. HPB (Oxford). 2016;18(6):523-28.

  7. Shi W, Jiang R, Liang F, Yu G, Long J, Zhao J. Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer. Cancer Manage Res. 2019;11:5065-73.

  8. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(23):5591-96.

  9. Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, Hu G, Sun Y. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med. 2015;13:45.

  10. George SJ, Johnson JL, Smith MA, Jackson CL. Plasmin-mediated fibroblast growth factor-2 mobilisation supports smooth muscle cell proliferation in human saphenous vein. J Vasc Res. 2001;38(5):492-501.

  11. Tysnes BB, Bjerkvig R. Cancer initiation and progression: involvement of stem cells and the microenvironment. Biochim Biophys Acta. 2007;1775(2):283-97.

  12. Aggarwal N, Sloane BF. Cathepsin B: multiple roles in cancer. Proteom Clin Appl. 2014;8(5-6):427-37.

  13. Lakkakula B, Farran B, Lakkakula S, Peela S, Yarla NS, Bramhachari PV, Kamal MA, Saddala MS, Nagaraju GP. Small molecule tyrosine kinase inhibitors and pancreatic cancer.

  14. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer. 2008;8(12):967-75.

  15. Katagiri T, Kobayashi M, Yoshimura M, Morinibu A, Itasaka S, Hiraoka M, Harada H. HIF-1 maintains a functional relationship between pancreatic cancer cells and stromal fibroblasts by upregulating expression and secretion of Sonic hedgehog. Oncotarget. 2018;9(12):10525-35.

  16. Onishi H, Katano M. Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer. World J Gastroenterol. 2014;20(9):2335-42.

  17. Rosow DE, Liss AS, Strobel O, Fritz S, Bausch D, Valsangkar NP, Alsina J, Kulemann B, Park JK, Yamaguchi J, LaFemina J, Thayer SP. Sonic Hedgehog in pancreatic cancer: from bench to bedside, then back to the bench. Surgery. 2012;152(301):S19-S32.

  18. Toft J, Hadden WJ, Laurence JM, Lam V, Yuen L, Janssen A, Pleass H. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: a systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy. Eur J Radiol. 2017;92:17-23.

  19. Raptopoulos V, Steer ML, Sheiman RG, Vrachliotis TG, Gougoutas CA, Movson JS. The use of helical CT and CT angiography to predict vascular involvement from pancreatic cancer: correlation with findings at surgery. Am J Roentgenol. 1997;168(4):971-77.

  20. Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol. 2014;20(24):7864-77.

  21. Griffin N, Charles-Edwards G, Grant LA. Magnetic resonance cholangiopancreatography: the ABC of MRCP. Insight Imag. 2011;3(1):11-21.

  22. Meng Z, Xu YK, Zhang YP. Magnetic resonance cholangiopancreatography of pancreaticobiliary duct dilation due to pancreatic carcinoma and chronic pancreatitis. Nan fang yi ke da xue xue bao = J Southern Med Univ. 2008;28(1):113-15 (in Chinese).

  23. Jha P, Bijan B. PET/CT for pancreatic malignancy: potential and pitfalls. J Nuclear Med Technol. 2015;43(2):92-97.

  24. Sperti C, Pasquali C, Bissoli S, Chierichetti F, Liessi G, Pedrazzoli S. Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT. J Gastrointest Surg. 2010;14(1):131-40.

  25. Bhaskar LVKS and Saikrishna L. Chapter 11: Molecular markers for treatment response and toxicity of gemcitabine. In: Nagaraju GP, editor. Breaking tolerance to pancreatic cancer unresponsiveness to chemotherapy, volume 5. San Diego, CA: Elsevier Inc./Academic Press; 2019.

  26. Andren-Sandberg A. Pancreatic cancer: chemotherapy and radiotherapy. N Am J Med Sci. 2011;3(1):1-12.

  27. Limbach LK, Li Y, Grass RN, Brunner TJ, Hintermann MA, Muller M, Gunther D, Stark WJ. Oxide nanoparticle uptake in human lung fibroblasts: effects of particle size, agglomeration, and diffusion at low concentrations. Environ Sci Technol. 2005;39(23):9370-76.

  28. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond). 2008;3(5):703-17.

  29. Salatin S, Maleki Dizaj S, Yari Khosroushahi A. Effect of the surface modification, size, and shape on cellular uptake ofnanoparticles. Cell Biol Int. 2015;39(8):881-90.

  30. Lee YJ, Ahn E-Y, Park Y. Shape-dependent cytotoxicity and cellular uptake of gold nanoparticles synthesized using green tea extract. Nanoscale Res Lett. 2019;14(1):129.

  31. Li J, Li JEJ, Zhang J, Wang X, Kawazoe N, Chen G. Gold nanoparticle size and shape influence on osteogenesis of mesenchymal stem cells. Nanoscale. 2016;8(15):7992-8007.

  32. Behzadi S, Serpooshan V, Tao W, Hamaly MA, Alkawareek MY, Dreaden EC, Brown D, Alkilany AM, Farokhzad OC, Mahmoudi M. Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev. 2017;46(14):4218-44.

  33. Pavitra E, Dariya B, Srivani G, Kang SM, Alam A, Sudhir PR, Kamal MA, Raju GSR, Han YK, Lakkakula B, Nagaraju GP, Huh YS. Engineered nanoparticles for imaging and drug delivery in colorectal cancer. Semin Cancer Biol. 2019.

  34. Thomas D, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 2019;18(1):14.

  35. Bisht S, Mizuma M, Feldmann G, Ottenhof NA, Hong SM, Pramanik D, Chenna V, Karikari C, Sharma R, Goggins MG, Rudek MA, Ravi R, Maitra A, Maitra A. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol Cancer Ther. 2010;9(8):2255-64.

  36. Yallapu MM, Ebeling MC, Khan S, Sundram V, Chauhan N, Gupta BK, Puumala SE, Jaggi M, Chauhan SC. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther. 2013;12(8):1471-80.

  37. Welser K, Adsley R, Moore BM, Chan WC, Aylott JW. Protease sensing with nanoparticle based platforms. The Analyst. 2011;136(1):29-41.

  38. Anderson CF, Cui H. Protease-sensitive nanomaterials for 50. cancer therapeutics and imaging. Industrial Eng Chem Res. 2017;56(20):5761-77.

  39. Kulkarni PS, Haldar MK, Nahire RR, Katti P, Ambre AH, Muhonen WW, Shabb JB, Padi SK, Singh RK, Borowicz PP, Shrivastava DK, Katti KS, Reindl K, Guo B, Mallik S. Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer. Mol Pharm. 2014;11(7):2390-99.

  40. Rochani AK, Balasubramanian S, Ravindran Girija A, Raveendran S, Borah A, Nagaoka Y, Nakajima Y, Maekawa T, Kumar DS. Dual mode of cancer cell destruction for pancreatic cancer therapy using Hsp90 inhibitor loaded polymeric nano magnetic formulation. Int J Pharma. 2016;511(1):648-58.

  41. Anajafi T, Yu J, Sedigh A, Haldar MK, Muhonen WW, Oberlander S, Wasness H, Froberg J, Molla MS, 53. Katti KS, Choi Y, Shabb JB, Srivastava DK, Mallik S. Nuclear localizing peptide-conjugated, redox-sensitive polymersomes for delivering curcumin and doxorubicin to pancreatic cancer microtumors. Mol Pharm. 2017;14(6):1916-28.

  42. Lu J, Yoshimura K, Goto K, Lee C, Hamura K, Kwon O, Tamanoi F. Nanoformulation of geranylgeranyltransferase-i inhibitors for cancer therapy: liposomal encapsulation and pH-dependent delivery to cancer cells. PLoS One. 2015;10(9):e0137595.

  43. Seifu MF, Nath LK. Polymer-drug conjugates: novel carriers for cancer chemotherapy. Polymer-Plastics Technol Mater. 2019;58(2):158-71.

  44. Mittal A, Chitkara D, Behrman SW, Mahato RI. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials. 2014;35(25):7077-87.

  45. Khare V, Sakarchi WA, Gupta PN, Curtis ADM, Hoskins C. Synthesis and characterization of TPGS-gemcitabine prodrug micelles for pancreatic cancer therapy. RSC Adv. 2016;6(65):60126-37.

  46. Wang L, Liu X, Zhou Q, Sui M, Lu Z, Zhou Z, Tang J, Miao Y, Zheng M, Wang W, Shen Y. Terminating the criminal collaboration in pancreatic cancer: nanoparticle based synergistic therapy for overcoming fibroblast- 58. induced drug resistance. Biomaterials. 2017;144:105-18.

  47. Joubert F, Martin L, Perrier S, Pasparakis G. Development of a gemcitabine-polymer conjugate with prolonged cytotoxicity against a pancreatic cancer cell line. ACS Macro Lett. 2017;6(5):535-40.

  48. Savariar EN, Aathimanikandan SV, Thayumanavan S. Supramolecular assemblies from amphiphilic homopolymers: testing the scope. J Am Chem Soc. 2006;128(50):16224-30.

  49. Kesharwani P, Banerjee S, Padhye S, Sarkar FH, Iyer AK. Parenterally administrable nano-micelles of 3,4-difluorobenzylidene curcumin for treating pancreatic cancer. Colloid Surf B, Biointerf. 2015;132:138-45.

  50. Ahn J, Miura Y, Yamada N, Chida T, Liu X, Kim A, Sato R, Tsumura R, Koga Y, Yasunaga M, Nishiyama N, Matsumura Y, Cabral H, Kataoka K. Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer. Biomaterials. 2015;39:23-30.

  51. Veeren A, Bhaw-Luximon A, Mukhopadhyay D, Jhurry D. Mixed poly(vinyl pyrrolidone)-based drug-loaded nanomicelles shows enhanced efficacy against pancreatic cancer cell lines. Eur J Pharma Sci. 2017;102:250-60.

  52. Hoskins C, Ouaissi M, Lima SC, Cheng WP, Loureirio I, Mas E, Lombardo D, Cordeiro-da-Silva A, Ouaissi A, Kong Thoo Lin P. In vitro and in vivo anticancer activity of a novel nano-sized formulation based on self-assembling polymers against pancreatic cancer. Pharm Res. 2010;27(12):2694-703.

  53. Eichhorn ME, Ischenko I, Luedemann S, Strieth S, Papyan A, Werner A, Bohnenkamp H, Guenzi E, Preissler G, Michaelis U, Jauch KW, Bruns CJ, Dellian M. Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer. 2010;126(5):1235-45.

  54. Saif MW, Podoltsev NA, Rubin MS, Figueroa JA, Lee MY, Kwon J, Rowen E, Yu J, Kerr RO. Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest. 2010;28(2):186-94.

  55. Aryal S, Hu CM, Zhang L. Combinatorial drug conjugation enables nanoparticle dual-drug delivery. Small (Weinheim an der Bergstrasse, Germany). 2010;6(13):1442-48.

  56. Poon C, He C, Liu D, Lu K, Lin W. Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer. J Control Release. 2015;201:90-99.

  57. Kesharwani P, Xie L, Banerjee S, Mao G, Padhye S, Sarkar FH, Iyer AK. Hyaluronic acid-conjugated polyamidoamine dendrimers for targeted delivery of 3,4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells. Colloid Surf B, Biointerf. 2015;136:413-23.

  58. Ozturk K, Esendagli G, Gurbuz MU, Tulu M, Calis S. Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers. Int J Pharmaceut. 2017;517(1-2):157-67.

  59. Mattu C, Brachi G, Ciardelli G. 2-Smart polymeric nanoparticles. In: Ciofani G, editor. Smart nanoparticles for biomedicine. Elsevier; 2018. pp 15-29.

  60. Emamzadeh M, Desmaele D, Couvreur P, Pasparakis G. Dual controlled delivery of squalenoyl-gemcitabine and paclitaxel using thermoresponsive polymeric micelles for pancreatic cancer. J Mater Chem B. 2018;6(15):2230-39.

  61. Li X, Szewczuk MR, Malardier-Jugroot C. Folic acid- conjugated amphiphilic alternating copolymer as a new active tumor targeting drug delivery platform. Drug Des Devel Ther. 2016;10:4101-10.

  62. Rapoport NY, Kennedy AM, Shea JE, Scaife CL, Nam KH. Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles. J Control Release. 2009;138(3):268-76.

  63. Larsen MT, Kuhlmann M, Hvam ML, Howard KA. Albumin-based drug delivery: harnessing nature to cure disease. Mol Cellular Ther. 2016;4:3.

  64. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin 73 Oncol. 2011;29(34):4548-54.

  65. Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer 74 Discov. 2012;2(3):260-69.

  66. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-703.

  67. Meng H, Wang M, Liu H, Liu X, Situ A, Wu B, Ji Z, Chang CH, Nel AE. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano. 2015;9(4):3540-57.

  68. Arachchige MP, Laha SS, Naik AR, Lewis KT, Naik R, Jena BP. Functionalized nanoparticles enable tracking the rapid entry and release of doxorubicin in human pancreatic cancer cells. Micron (Oxford, UK: 1993). 2017;92:25-31.

  69. Trabulo S, Aires A, Aicher A, Heeschen C, Cortajarena AL. Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells. Biochimica Biophysica Acta. 2017;1861(6):1597-605.

  70. Malekigorji M, Alfahad M, Kong Thoo Lin P, Jones S, Curtis A, Hoskins C. Thermally triggered theranostics for pancreatic cancer therapy. Nanoscale. 2017;9(34): 12735-45.

  71. Oluwasanmi A, Al-Shakarchi W, Manzur A, Aldebasi MH, Elsini RS, Albusair MK, Haxton KJ, Curtis ADM, Hoskins C. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy. J Control Release. 2017;266:355-64.

  72. Zhao J, Wu C, Abbruzzese J, Hwang RF, Li C. Cyclopamine-loaded core-cross-linked polymeric micelles enhance radiation response in pancreatic cancer and pancreatic stellate cells. Mol Pharm. 2015;12(6):2093-100.

  73. Zhao J, Wu C, Wen X, Li J, Huang Q, Ma Y, Ullrich S, Wang H, Fleming J, Li C. Abstract 1318: Pancreatic cancer therapy using polyion micelles co-loaded with cyclopamine and paclitaxel. Cancer Res. 2016;76(14 Suppl):1318-18.

  74. Zhao J, Wang H, Hsiao C-H, Chow DSL, Koay EJ, Kang Y, Wen X, Huang Q, Ma Y, Bankson JA, Ullrich SE, Overwijk W, Maitra A, Piwnica-Worms D, Fleming JB, Li C. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Biomaterials. 2018;159:215-28.

  75. Lee N, Kim H, Choi SH, Park M, Kim D, Kim HC, Choi Y, Lin S, Kim BH, Jung HS, Kim H, Park KS, Moon WK, Hyeon T. Magnetosome-like ferrimagnetic iron oxide nanocubes for highly sensitive MRI of single cells and transplanted pancreatic islets. Proc Natl Acad Sci U S A. 2011;108(7):2662-67.

Articles with similar content:

Nanotechnology: An Emerging Therapeutic Option for Breast Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.28, 2018, issue 2
Sehrish Murtaza, Zulfia Hussain, Junaid Ali Khan
Druggable Targets in Pancreatic Adenocarcinoma
Onco Therapeutics, Vol.5, 2014, issue 3-4
Cristina Napoli, Stefania Nobili, Ida Landini, Gabriele Perrone, Enrico Mini, Renato Tassi
Therapeutic Opportunities in Colon-Specific Drug-Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 2
Avani Amin, Mayur M. Patel, Tejal Shah
Recent Advances in Nanoparticle-Based Targeted Drug-Delivery Systems Against Cancer and Role of Tumor Microenvironment
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 4
Usman Ali Ashfaq, Muhammad Zubair Yousaf, Erum Yasmeen, Muhammad Riaz
Current Perspectives on Novel Drug Carrier Systems and Therapies for Management of Pancreatic Cancer: An Updated Inclusive Review
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 3
Rohit R. Bhosale, Bannimath Gurupadayya, Devegowda Vishakante Gowda, Koganti Venkata Sairam, Riyaz Ali Mahafez Ali Osmani, Rudra Vaghela, Hosahalli Veerabhadrappa Gangadharappa, Parthasarathi Keshavarao Kulkarni